10 clinical trials found.
-
A Phase I/II study Evaluating the Dosing Safety Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer
You are being asked to take part in this study because you have epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer and you ...Phase
TRIAL ROLE: Sub Investigator
-
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2 Stage II IIIB or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
If you have been diagnosed with locally advanced cervical or vaginal cancer, you may qualify for this Phase II study evaluating the investigational drug triapine ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1b First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b
The purpose of the study is to determine the safety and tolerability of the antibody-drug conjugate (ADC) XMT-1536 administered as an intravenous infusion once every ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase III Randomized Placebo-Controlled Study of Pembrolizumab (MK-3475 NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA Stage IVB or Recurrent Endometrial Cancer
The purpose of the study is to determine if we can lower the chance of your endometrial cancer growing or spreading by adding a new ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
The purpose of the study is to compares whether the addition of pembrolizumab to radiation therapy is more effective than radiation therapy alone in reducing ...Phase
TRIAL ROLE: Sub Investigator
-
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)
The purpose of the study is to determine the safety and efficacy of INCMGA00012 monotherapy or in combination with other immunotherapy or targeted agents (combinations ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 3 Randomized Double-Blind Study of Pembrolizumab versus Placebo in Combination with Adjuvant Chemotherapy with or without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Carcinoma After Surgery with Curative Intent (MK3475 B21/ENGOT-en11/GOG-3053)
The purpose of the study is to determine and compare pembrolizumab and adjuvant chemotherapy with placebo and adjuvant chemotherapy, with or without radiotherapy, in relation ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1 Open-Label Safety Pharmacokinetic and Preliminary Efficacy Study of STRO-002 an Anti-Folate Receptor Alpha (FolRa) Antibody-Drug Conjugate (ADC) in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
The purpose of the study is to determine the safety and efficacy of STRO-002, which is a antibody drug conjugate (ADC) given intravenously every 3 ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ ) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors
The purpose of the study to determine the efficacy of TJ004309 (anti- CD-73 ab )in combination with atezolizumab (PDL-1 inhibitor) immunotherapy in patients with advanced ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.
The purpose of the study is to evaluateTRK-950 in combination with 1) FOLFIRI or 2) Gemcitabine / Cisplatin or 3) Gemcitabine / Carboplatin or 4) Ramucirumab/Paclitaxel ...Phase
TRIAL ROLE: Sub Investigator
